IL-6 and soluble IL-2 receptor in rheumatoid arthritis patients treated with second line drugs.
Watson
J
J
Dept. of Bioscience & Biotechnology, University of Strathclyde, Todd Centre, Glasgow.
Crilly
A
A
Madhok
R
R
Capell
H
H
Sturrock
R
R
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D006052:Gold Sodium Thiomalate / Q000627:therapeutic use*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D015375:Receptors, Interleukin-2 / Q000187:drug effects / Q000378:metabolism*; D012460:Sulfasalazine / Q000627:therapeutic use*
D015850:Interleukin-6; D015375:Receptors, Interleukin-2; D006052:Gold Sodium Thiomalate; D012460:Sulfasalazine